Tags

Type your tag names separated by a space and hit enter

Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
Thromb Haemost 1992; 67(3):292-6TH

Abstract

Progressive thrombocytopenia may develop in as many as 5% of patients receiving heparin anticoagulation. In these patients, the risk of thromboembolic complications as well as continued thrombocytopenia necessitates discontinuation of heparin and initiation of an alternative anticoagulant when indicated. The heparinoid Lomoparan (Org 10172) is a mixture of several non-heparin low molecular weight glycosaminoglycans with proven anticoagulant efficacy that is generally non-reactive with platelets in the presence of plasma from patients with heparin induced thrombocytopenia, whereas standard heparin will induce platelet aggregation. We evaluated the role of heparinoid as a potential alternative anticoagulant in patients with heparin induced thrombocytopenia. During a 6 month period, we identified six patients with heparin induced thrombocytopenia who required an alternative parenteral anticoagulant, four as primary treatment for specific medical problem, and two as anticoagulation during a necessary surgical procedure. Heparinoid was used successfully in both medical and surgical patients requiring parenteral anticoagulation. In no case was there an exacerbation of the thrombocytopenia nor thromboembolic complications while on heparinoid therapy. Three of our patients sustained hemorrhagic complications, predominantly in the post-surgical setting in association with elevated anti-factor Xa levels and additional anticoagulant agents. We feel that these results confirm the utility of heparinoid anticoagulation in a select subset of patients with heparin induced thrombocytopenia who require continued parenteral anticoagulation.

Authors+Show Affiliations

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1379384

Citation

Ortel, T L., et al. "Parenteral Anticoagulation With the Heparinoid Lomoparan (Org 10172) in Patients With Heparin Induced Thrombocytopenia and Thrombosis." Thrombosis and Haemostasis, vol. 67, no. 3, 1992, pp. 292-6.
Ortel TL, Gockerman JP, Califf RM, et al. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemost. 1992;67(3):292-6.
Ortel, T. L., Gockerman, J. P., Califf, R. M., McCann, R. L., O'Connor, C. M., Metzler, D. M., & Greenberg, C. S. (1992). Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thrombosis and Haemostasis, 67(3), pp. 292-6.
Ortel TL, et al. Parenteral Anticoagulation With the Heparinoid Lomoparan (Org 10172) in Patients With Heparin Induced Thrombocytopenia and Thrombosis. Thromb Haemost. 1992 Mar 2;67(3):292-6. PubMed PMID: 1379384.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. AU - Ortel,T L, AU - Gockerman,J P, AU - Califf,R M, AU - McCann,R L, AU - O'Connor,C M, AU - Metzler,D M, AU - Greenberg,C S, PY - 1992/3/2/pubmed PY - 1992/3/2/medline PY - 1992/3/2/entrez SP - 292 EP - 6 JF - Thrombosis and haemostasis JO - Thromb. Haemost. VL - 67 IS - 3 N2 - Progressive thrombocytopenia may develop in as many as 5% of patients receiving heparin anticoagulation. In these patients, the risk of thromboembolic complications as well as continued thrombocytopenia necessitates discontinuation of heparin and initiation of an alternative anticoagulant when indicated. The heparinoid Lomoparan (Org 10172) is a mixture of several non-heparin low molecular weight glycosaminoglycans with proven anticoagulant efficacy that is generally non-reactive with platelets in the presence of plasma from patients with heparin induced thrombocytopenia, whereas standard heparin will induce platelet aggregation. We evaluated the role of heparinoid as a potential alternative anticoagulant in patients with heparin induced thrombocytopenia. During a 6 month period, we identified six patients with heparin induced thrombocytopenia who required an alternative parenteral anticoagulant, four as primary treatment for specific medical problem, and two as anticoagulation during a necessary surgical procedure. Heparinoid was used successfully in both medical and surgical patients requiring parenteral anticoagulation. In no case was there an exacerbation of the thrombocytopenia nor thromboembolic complications while on heparinoid therapy. Three of our patients sustained hemorrhagic complications, predominantly in the post-surgical setting in association with elevated anti-factor Xa levels and additional anticoagulant agents. We feel that these results confirm the utility of heparinoid anticoagulation in a select subset of patients with heparin induced thrombocytopenia who require continued parenteral anticoagulation. SN - 0340-6245 UR - https://www.unboundmedicine.com/medline/citation/1379384/Parenteral_anticoagulation_with_the_heparinoid_Lomoparan__Org_10172__in_patients_with_heparin_induced_thrombocytopenia_and_thrombosis_ L2 - http://www.diseaseinfosearch.org/result/3326 DB - PRIME DP - Unbound Medicine ER -